Daiwa Securities Group Portfolio holdings
AUM
$27.1B
1-Year Return
23.24%
This Quarter Return
+0.37%
1 Year Return
+23.24%
3 Year Return
+64.59%
5 Year Return
+118.48%
10 Year Return
+210.79%
AUM
$15.2B
AUM Growth
+$365M
(+2.5%)
Cap. Flow
+$16.5M
Cap. Flow
% of AUM
0.11%
Top 10 Holdings %
Top 10 Hldgs %
31.7%
Holding
1,372
New
93
Increased
870
Reduced
195
Closed
27
Top Buys
| 1 |
Invitation Homes
INVH
|
$168M |
| 2 |
Welltower
WELL
|
$142M |
| 3 |
Cousins Properties
CUZ
|
$117M |
| 4 |
Digital Realty Trust
DLR
|
$95.2M |
| 5 |
VICI Properties
VICI
|
$90.1M |
Top Sells
| 1 |
Equinix
EQIX
|
$253M |
| 2 |
Sun Communities
SUI
|
$162M |
| 3 |
Extra Space Storage
EXR
|
$136M |
| 4 |
Kilroy Realty
KRC
|
$99.8M |
| 5 |
American Tower
AMT
|
$95.7M |
Sector Composition
| 1 | Real Estate | 55.89% |
| 2 | Technology | 9.18% |
| 3 | Communication Services | 4.61% |
| 4 | Consumer Discretionary | 4.25% |
| 5 | Financials | 3.6% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1151
Nurix Therapeutics
NRIX
$758M
| $5K | ﹤0.01% |
152
+79
| +108% | +$2.6K |
|
1152
Vaxcyte
PCVX
$4.29B
| $5K | ﹤0.01% |
179
+83
| +86% | +$2.32K |
|
1153
uniQure
QURE
$985M
| $5K | ﹤0.01% |
158
+74
| +88% | +$2.34K |
|
1154
Replimune Group
REPL
$494M
| $5K | ﹤0.01% |
160
+74
| +86% | +$2.31K |
|
1155
Supernus Pharmaceuticals
SUPN
$2.58B
| $5K | ﹤0.01% |
182
+83
| +84% | +$2.28K |
|
1156
Travere Therapeutics
TVTX
$1.93B
| $5K | ﹤0.01% |
208
+94
| +82% | +$2.26K |
|
|
RUBY
1157
DELISTED
Rubius Therapeutics, Inc
RUBY
| $5K | ﹤0.01% |
307
+129
| +72% | +$2.1K |
|
|
GBT
1158
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $5K | ﹤0.01% |
214
+98
| +84% | +$2.29K |
|
|
DRNA
1159
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
| $5K | ﹤0.01% |
266
+125
| +89% | +$2.35K |
|
|
KDMN
1160
DELISTED
Kadmon Holdings, Inc.
KDMN
| $5K | ﹤0.01% |
590
+267
| +83% | +$2.26K |
|
1161
Arcutis Biotherapeutics
ARQT
$2.06B
| $4K | ﹤0.01% |
172
+73
| +74% | +$1.7K |
|
1162
Axsome Therapeutics
AXSM
$6.25B
| $4K | ﹤0.01% |
129
+59
| +84% | +$1.83K |
|
|
BLUE
1163
DELISTED
bluebird bio
BLUE
| $4K | ﹤0.01% |
18
+8
| +80% | +$1.78K |
|
1164
Coherus Oncology, Inc. Common Stock
CHRS
$150M
| $4K | ﹤0.01% |
262
+127
| +94% | +$1.94K |
|
1165
Enanta Pharmaceuticals
ENTA
$189M
| $4K | ﹤0.01% |
69
+31
| +82% | +$1.8K |
|
1166
Fulcrum Therapeutics
FULC
$414M
| $4K | ﹤0.01% |
138
+86
| +165% | +$2.49K |
|
1167
Krystal Biotech
KRYS
$4.35B
| $4K | ﹤0.01% |
76
+33
| +77% | +$1.74K |
|
1168
Kura Oncology
KURA
$713M
| $4K | ﹤0.01% |
227
+96
| +73% | +$1.69K |
|
1169
MacroGenics
MGNX
$126M
| $4K | ﹤0.01% |
209
+103
| +97% | +$1.97K |
|
1170
MannKind Corp
MNKD
$1.7B
| $4K | ﹤0.01% |
855
-99,582
| -99% | -$466K |
|
1171
Precigen
PGEN
$1.3B
| $4K | ﹤0.01% |
708
+307
| +77% | +$1.73K |
|
1172
Avidity Biosciences
RNA
$6.48B
| $4K | ﹤0.01% |
156
+85
| +120% | +$2.18K |
|
1173
Sangamo Therapeutics
SGMO
$165M
| $4K | ﹤0.01% |
498
+232
| +87% | +$1.86K |
|
1174
Scholar Rock
SRRK
$3.02B
| $4K | ﹤0.01% |
118
+55
| +87% | +$1.86K |
|
1175
Y-mAbs Therapeutics
YMAB
$390M
| $4K | ﹤0.01% |
149
+73
| +96% | +$1.96K |
|